This HTML5 document contains 83 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n14https://global.dbpedia.org/id/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n15http://
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Statera_BioPharma
rdf:type
n3:Agent dbo:Agent wikidata:Q24229398 dbo:Organisation dbo:Company owl:Thing schema:Organization wikidata:Q4830453 wikidata:Q43229 n3:SocialPerson
rdfs:label
Statera BioPharma
rdfs:comment
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma".
foaf:name
Statera BioPharma, Inc.
dbp:name
Statera BioPharma, Inc.
dcterms:subject
dbc:Biotechnology_companies_of_the_United_States dbc:Biotechnology_companies_established_in_2003 dbc:Companies_listed_on_the_Nasdaq dbc:2003_establishments_in_Ohio
dbo:wikiPageID
24342211
dbo:wikiPageRevisionID
1088537289
dbo:wikiPageWikiLink
dbr:Immunotherapy dbc:Biotechnology_companies_of_the_United_States dbr:Roman_Abramovich dbr:Entolimod dbr:Public_company dbr:Armed_Forces_Radiobiology_Research_Institute dbr:Russian_Federation dbr:Cleveland_Clinic dbr:Acute_radiation_syndrome dbr:Buffalo_Niagara_Medical_Campus dbr:Animal_efficacy_rule dbr:Mycoplasma dbr:Fort_Collins,_Colorado dbr:Rusnano dbr:HSF1 dbc:Companies_listed_on_the_Nasdaq dbr:In_vitro dbr:Quinacrine dbc:Biotechnology_companies_established_in_2003 dbr:P53 dbr:Roswell_Park_Comprehensive_Cancer_Center dbc:2003_establishments_in_Ohio dbr:NF-kB dbr:TLR2 dbr:TLR_5 dbr:Cleveland,_Ohio dbr:FACT_(biology) dbr:Food_and_Drug_Administration dbr:TLR6
dbo:wikiPageExternalLink
n15:www.incuron.com n15:www.panacelalabs.com n15:www.cbiolabs.com
owl:sameAs
wikidata:Q5132065 n14:4hpE2
dbp:wikiPageUsesTemplate
dbt:As_of dbt:Infobox_company dbt:URL dbt:Reflist dbt:Pharmaceutical_companies_of_the_United_States dbt:Clarify
dbp:date
April 2020
dbp:formerName
Cytocom Cleveland BioLabs
dbp:foundation
Cleveland, Ohio, 2003
dbp:industry
Pharmaceuticals
dbp:keyPeople
Yakov Kogan, CEO
dbp:locationCity
dbr:Fort_Collins,_Colorado
dbp:locationCountry
USA
dbp:products
Anti-radiation and oncological products
dbp:reason
Does "a quinacrine" refer to a quinacrine derivative or to quinacrine itself?
dbp:subsid
Panacela Labs, Inc. Incuron, LLC
dbp:tradedAs
NASDAQ:STAB
dbp:type
dbr:Public_company
dbo:abstract
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma". Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.Genome Protection Inc. subsequently received a $10.5 million (US) investment from Russian oligarch Roman Abramovich.
prov:wasDerivedFrom
wikipedia-en:Statera_BioPharma?oldid=1088537289&ns=0
dbo:wikiPageLength
9366
dbo:formerName
Cleveland BioLabs Cytocom
dbo:foundingYear
2003-01-01
dbo:type
dbr:Public_company
foaf:isPrimaryTopicOf
wikipedia-en:Statera_BioPharma